Phase 1 Mesothelioma Trial, Recruiting NCT06444815 Sponsor: KaliVir Immunotherapeutics Condition: Mesothelioma
Back to Mesothelioma

Phase 1 Mesothelioma Trial, Recruiting

NCT06444815
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with an advanced, inoperable, or spreading solid tumour that has been confirmed by a lab test (pathology).
  • Your cancer is one of several types of interest, including breast, bladder, cervical, colorectal, oesophageal, head and neck, kidney, ovarian, sarcoma, thymoma, or uterine cancer (other types may also be considered).
  • You have already tried standard treatments, were unable to tolerate them, or have chosen not to pursue them — this may include targeted therapies, immunotherapy, or chemotherapy.
  • Your cancer can be measured on scans according to a standard set of guidelines (called RECIST 1.1).
  • You have at least one tumour that doctors can safely inject into or take a biopsy from.
  • You are generally well enough to carry out light activity and care for yourself (this is assessed using a standard fitness scale — confirm with trial site).
  • Your liver, kidneys, and other organs are working well enough to meet the trial's requirements (confirm with trial site).
  • You are willing and able to follow all trial procedures and aftercare instructions.
  • Additional eligibility requirements may also apply (confirm with trial site).

Who may not be able to join:

  • You have recently received certain cancer treatments and have not yet waited the required amount of time since finishing them (the exact waiting period depends on the treatment type — confirm with trial site).
  • You are taking blood-thinning or anti-clotting medications that cannot be safely stopped for the biopsies or injections required by the trial.
  • You have cancer that has spread to the brain or the lining around the brain/spine, and it has not been fully removed by surgery or treated with radiation.
  • You have a previous history of inflammation of the heart muscle (myocarditis).
  • You have HIV/AIDS, or a currently active hepatitis B or hepatitis C infection.
  • You are taking high-dose medications that suppress your immune system, or you have a significant problem with your immune system (for example, if you have had an organ transplant).
  • Additional reasons that may prevent participation also exist (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +13057722084

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
KaliVir Immunotherapeutics
Registry
ClinicalTrials.gov
Start date
16 September 2024
Est. completion
30 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of adverse events with VET3-TGI alone or in combination with atezolizumab; Incidence of dose limiting toxicities reported with VET3-TGI alone or in combination with atezolizumab; Determine the recommended Phase 2 dose

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov